Prostate cancer prospects dashed for Takeda's orteronel
This article was originally published in Scrip
Hopes have faded for Takeda's orteronel in prostate cancer after it failed to meet the all-important primary endpoint of overall survival (OS) in the ELM-PC4 pivotal Phase III trial. The drug was shown to reduce the risk of radiographic progression free survival (rPFS), the other primary endpoint.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.